Ms. Jane Wasman has been the Chairman of the company since 2023. Previously, she served as a director of the company. She is Founder and President of JWasman Advisors. She served as President, International and General Counsel at Acorda Therapeutics.

Mr. Daniel A. Camardo has been Chief Executive Officer and Director of the company since 2022. Prior to this He served as Executive Vice President and Head of the Rare Disease and Inflammation Business Units and President at Horizon Therapeutics. Earliet, he worked in various leadership roles for few other biotechnology and pharmaceutical companies, which includes Astellas and has been involved in more than 10 medicine launches across various therapeutic areas, small molecules and biologics.

Ms. Maia Hanson has been the Chief Operating Officer of the company since June 2022 and previously he served as Senior Vice President of Operations & Supply Chain in 2020. She has an extensive experience in Operations and Supply Chain in the sectors of Pharmaceuticals, Consumer Health and Medical device sectors. Prior to this, Ms. Hansan has served as Senior Partner at McKinsey & Company; and as Managing Partner at McKinsey’s Cleveland Office.

Ms. Kasey Rosado has been the Interim Chief Financial Officer of the company since August 2022. Prior to this she served as a Senior Managing Director and Managing Director of Ankura Consulting Group LLC.